According to “News by the Minute”, The new recommendations, published in the medical journal The BMJ by WHO experts, suggest treatment with synthetic antibodies — sotrovimab — and a drug used in the treatment of rheumatoid arthritis — baricitinib. Both are not intended for all patients, reports the AFP agency. that the benefit for patients who are not at risk is considered very low. Baricitinib is recommended for “patients with severe or critical covid-19”, and the treatment should be done “in combination with corticosteroids”. In these patients, the treatment “increases survival rates and reduces the need for mechanical ventilation”. severe or critical illness and the monoclonal antibodies casirivimab and imdevimab in selected patients. On the other hand, the World Health Organization already advised against the treatment of covid-19 with convalescent plasma, with the antiparasitic ivermectin and with the antimalarial hydroxychloroquine, regardless of the degree of severity of the disease. disease.Sotrovimab affects the same type of patients as Ronapreve and “its effectiveness against new variants such as Ómicron is still uncertain”.Likewise, baricitinib “has the same effects” of IL-inhibiting drugs -6 and should be administered to the same patients.”When both are available”, it is therefore necessary to choose which of the two to use “according to cost, availability and the experience of caregivers”, underline the experts Other drugs in the baricitinib family – ruxolitinib and tofacitinib – should not be used against covid-19, due to lack of data on their efficacy or side effects, warns m.The recommendations on treatments against covid-19 by the WHO are updated regularly, based on clinical trials in different types of patients.But the therapeutic arsenal continues to be reduced, as the WHO has rejected the use of various treatments.

Tradução automática do artigo:Aceder ao artigo original

Leave a Reply

Your email address will not be published.